Reverb Therapeutics — Redirecting endogenous cytokines

This week, we are excited to launch our latest company — <a href="https://www.businesswire.com/news/home/20231115635574/en/" rel="noopener ugc nofollow" target="_blank">Reverb Therapeutics</a>. Reverb is the culmination of a 15-month internal company creation effort, working closely with highly experienced, repeat entrepreneurs in <a href="https://www.linkedin.com/in/davidd12/" rel="noopener ugc nofollow" target="_blank">David de Graaf</a> and <a href="https://www.linkedin.com/in/surjit-dixit-711b44/?originalSubdomain=ca" rel="noopener ugc nofollow" target="_blank">Surjit Dixit</a> to build a new platform leveraging insights from over thirty years of cytokine biology. The last ten years has seen several cytokine approaches emerge, including a few large partnerships and acquisitions, but none of these have translated into therapeutics. Cytokines can be very effective, but their mode of action provides a very narrow therapeutic window. Most approaches use lab-made cytokines or cytokine-related products which have failed to date due to toxicity, rapid clearance, immunogenicity and poor developability profiles. Many patients can get cytokine release syndrome, which can be deadlier than the disease itself <a href="https://amplitudevc.medium.com/reverb-therapeutics-redirecting-endogenous-cytokines-dfd700b25e06">Website</a>